Passive Immunity is a form of immunity that is transferred from one individual to another, providing immediate protection against a specific pathogen or toxin. Unlike active immunity, which is acquired through vaccination or natural infection and involves the production of antibodies by the recipient's own immune system, passive immunity involves the transfer of pre-formed antibodies from a donor to a recipient. Passive immunity can be acquired naturally or artificially. In natural passive immunity, antibodies are transferred from a mother to her foetus during pregnancy through the placenta, or from a mother to her infant through breast milk. These maternal antibodies provide temporary protection to the newborn against certain infectious diseases until their own immune system matures and begins producing antibodies independently.
Artificial passive immunity, on the other hand, involves the administration of pre-formed antibodies derived from human or animal sources. This can be achieved through the injection of immune serum or purified immunoglobulins obtained from individuals who have been previously immunized or infected with the target pathogen. These antibodies provide immediate, short-term protection against the specific pathogen. Passive immunity is often used as a prophylactic or therapeutic measure to prevent or treat infectious diseases, particularly in situations where active immunization is not feasible or when immediate protection is required. For example, passive immunization with immune globulin preparations is commonly used to prevent or mitigate the severity of diseases such as hepatitis A, hepatitis B, rabies, tetanus, and varicella (chickenpox).
In addition to infectious diseases, passive immunity can also be used to treat certain autoimmune disorders, such as immune thrombocytopenic purpura (ITP) and Kawasaki disease, as well as toxin-mediated conditions, such as botulism and diphtheria.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States